FDA Inspection 1301534 — Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. — FEI 3018815311

The FDA completed an inspection of Axsome Therapeutics, Inc. on February 6, 2026 in New York, NY. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 2 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
February 6, 2026
Fiscal Year
2026
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
New York, NY (United States)

Additional Details

Sponsor, Contract Research Organization

Citations

IDCFRDescription
748221 CFR 312.50General responsibilities of sponsors
755721 CFR 312.56(b)Notification of FDA of termination of investigator